Tumores del estroma gastrointestinal: revisión y manejo multidisciplinario

Gastrointestinal stromal tumors (GIST) comprise <1% of all gastrointestinal (GI) tumors, but GISTs are the most common mesenchymal tumors of the GI tract. Drastic changes in clinical practice have been observed in the last decade. Despite considerable progress in the diagnosis and treatment of GISTs, it is estimated that approximately half of all patients experience recurrence. The aim of the present study is to provide an up-to-date review of basic concepts about tumor and general management, in addition to recent developments. Articles with less than ten years of publication were analyzed, including review articles, meta-analysis and case reports; There was no language restriction for the selection of articles. Conclusion: This literature review clarifies some aspects of epidemiology, pathophysiology, immunohistochemistry, surgical treatment and adjuvant therapy. GISTs are rare tumors that represent a small percentage of gastrointestinal neoplasms and are usually positive for CD117 and DOG-1. Laparoscopic surgical resection is the gold standard for the treatment of GIST. Metastases are very common and can be seen in the liver, mesentery, and omentum. Adjuvant therapy with tyrosine kinase inhibitors is recommended in those patients with high-risk primary GISTs.